Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06783270RecruitingPhase 1
T-Cell Therapy for Advanced Melanoma
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Herlev, Capital RegionAges 18–75 - NCT06418061RecruitingPhase 1
Testing IBI3005 for advanced solid tumors
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
Jinan, ShandongAges 18 years+ - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07449754RecruitingPhase 2
Belvarafenib with cobimetinib for NRAS-mutant melanoma
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07418749RecruitingPhase 3
Testing a new drug for advanced cervical cancer after standard treatments
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Guangzhou, GuangdongAges 18 years+ - NCT07416552RecruitingPhase 1
Study of CEA-PRIT 2.0 for advanced colorectal cancer
This trial tests an experimental drug called CEA-PRIT 2.0 in people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Chicago, IllinoisAges 18 years+ - NCT07424664RecruitingPhase 2
Combination targeted drug and immunotherapy for recurrent gynecologic cancers
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Wuhan, HubeiAges 18–75 - NCT07422779Recruiting
Immunotherapy for advanced melanoma study
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
LjubljanaAges 18 years+ - NCT06293651RecruitingPhase 1/Phase 2
Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
SeoulAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Tucson, ArizonaAges 18 years+ - NCT07407504RecruitingPhase 1
Targeted therapy for cancers with a specific gene change
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07406282Recruiting
Darolutamide for new prostate cancer that spread
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Cleveland, OhioAges 18 years+ - NCT07404176RecruitingPhase 2
New radioactive drug for advanced neuroendocrine tumors
This trial tests a new radioactive drug, Terbium-161 DOTATATE, for people with advanced neuroendocrine tumors that have stopped responding to a similar treatment called Lu-177 DOTATATE. It aims to see if this new drug is safe and can help shrink tumors.
Mumbai, MaharashtraAges 18–70 - NCT06825624RecruitingPhase 1
Testing HS-20093 combinations for advanced colorectal cancer
This trial tests a new drug combination (HS-20093) for people with advanced colorectal cancer that has spread or cannot be removed by surgery. It aims to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT07407166Recruiting
Immunotherapy for first-line metastatic melanoma in Slovenia
This study follows people with melanoma that has spread to other organs who are receiving immunotherapy as their first treatment. Researchers want to see how well this therapy works and look for clues in the body that predict response.
LjubljanaAges 18 years+ - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT07393542RecruitingPhase 3
Combination treatment for advanced bladder cancer
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,342 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.